After Year-Long Review, Varmus Removes “Reasonable Pricing” Clause From CRADA
In Brief: Comis Named ECOG Chairman; Long Joins Capitol Associates; Chabner Day In Shelbyville
Advisors’ Report On Intramural Program To Recommend Restructuring
Russian-American Breast Cancer Meeting Canceled
Breast Cancer Plan Issues Its First RFA, Other Initiatives To Be Announced Soon
NCI, EORTC Offer Support For Russian Cancer Researchers
Public Forum On NRSA Tuition Policies
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
